Cannabis and Liver Disease UK – Safety and Evidence

Cannabis and Liver Disease UK: Safety and Evidence

Cannabis use remains a topic of considerable discussion in the United Kingdom, particularly regarding its interaction with liver health. With an estimated 3 million UK adults using cannabis annually, understanding how cannabis affects the liver is crucial for both recreational users and medical patients. This comprehensive guide examines the current evidence surrounding cannabis and liver disease in a UK context.

Understanding Liver Disease in the UK

Liver disease represents a significant public health challenge across the United Kingdom. The British Liver Trust reports that around 2.1 million people in the UK have advanced liver fibrosis or cirrhosis. Common causes include alcohol consumption, viral hepatitis, and fatty liver disease. With cannabis use increasing, particularly following the legalisation of medical cannabis in 2018, understanding potential interactions between cannabis and existing liver conditions has become increasingly important.

The liver plays a crucial role in metabolising substances, including cannabinoids. THC (tetrahydrocannabinol) and CBD (cannabidiol) are both processed through hepatic metabolism, making liver function particularly relevant for cannabis users.

How Cannabis Affects Liver Metabolism

When you consume cannabis, the liver metabolises cannabinoids through the cytochrome P450 enzyme system. This is the same pathway responsible for breaking down numerous medications and toxins. Research indicates that cannabis itself is not directly hepatotoxic, meaning it doesn’t directly damage liver cells in the way alcohol does.

However, a 2019 study published in the journal Hepatology found that cannabis use was associated with higher rates of fatty liver disease in some populations. The relationship appears complex and may depend on individual factors including genetics, existing liver health, duration of use, and method of consumption.

CBD, increasingly used in the UK for various conditions from anxiety to epilepsy, requires particular attention. Some evidence suggests CBD may elevate liver enzymes in rare cases, though serious hepatotoxicity remains uncommon. The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends monitoring liver function in patients taking high-dose CBD products.

Medical Cannabis and Liver Patients

Since the UK legalised medical cannabis in November 2018, patients with various conditions have accessed cannabis-based medicinal products. For patients with existing liver disease, medical use requires careful consideration and specialist guidance.

The British Association for Psychopharmacology notes that patients with significant liver dysfunction should use cannabis cautiously, as impaired liver function reduces the body’s ability to metabolise cannabinoids effectively. This can lead to increased cannabinoid accumulation and potential adverse effects.

Conversely, some evidence suggests cannabinoids may have anti-inflammatory properties that could theoretically benefit certain liver conditions. However, clinical evidence supporting cannabis treatment specifically for liver disease remains limited in UK practice.

Cannabis, Hepatitis, and Co-infections

The relationship between cannabis use and hepatitis deserves specific attention. A study from Queen Mary University of London found that cannabis smokers had higher prevalence rates of hepatitis C antibodies compared to non-users. However, this likely reflects shared risk factors including potential needle sharing and lifestyle patterns rather than cannabis directly causing hepatitis.

For patients with hepatitis B or C, cannabis use warrants careful assessment. These conditions already compromise liver function, and adding cannabis consumption may increase metabolic stress on an already damaged organ.

Method of Consumption Matters

How you consume cannabis significantly impacts liver health. Smoking cannabis creates additional burdens on the liver as it processes byproducts from combustion. Edibles and oils bypass the lungs but undergo first-pass hepatic metabolism, potentially concentrating effects on the liver.

For UK patients with liver concerns, vaporisation appears preferable to smoking, as it reduces harmful byproducts. Sublingual products like cannabis oils offer controlled dosing with potentially reduced hepatic stress compared to edibles.

Current UK Regulatory Stance

The MHRA has approved limited cannabis-based medicines in the UK, including Sativex for multiple sclerosis and Epidyolex for severe epilepsy. Both medications come with monitoring recommendations for patients with hepatic impairment. The licence information explicitly advises caution in patients with liver disease.

Private clinics prescribing medical cannabis in the UK typically conduct baseline liver function tests before commencing treatment, particularly for patients with risk factors. This represents best practice, even though evidence of cannabis directly causing liver damage remains limited.

Alcohol and Cannabis: Compounded Risks

The combination of cannabis and alcohol presents particular concerns for liver health. Alcohol is directly hepatotoxic and accounts for significant liver disease burden in the UK. Using cannabis alongside alcohol may compound hepatic stress, particularly in heavy users.

The Office for National Statistics reports alcohol-specific deaths have increased 39% since 2001, with liver disease being a primary factor. Adding cannabis to existing alcohol use amplifies metabolic demands on the liver.

What Evidence Shows About Safety

The current evidence base suggests cannabis is not inherently hepatotoxic in the way alcohol is. Acute liver failure directly attributable to cannabis remains exceptionally rare in the UK and globally. However, this doesn’t mean cannabis is entirely risk-free for those with existing liver disease.

A comprehensive review in Pharmaceuticals (2021) concluded that whilst cannabinoid-induced hepatotoxicity is uncommon, patients with pre-existing liver disease warrant more cautious approaches. The risk-benefit analysis differs substantially between healthy users and those with compromised liver function.

Practical Advice for UK Cannabis Users with Liver Concerns

If you have existing liver disease and use cannabis, consider the following:

• Inform your GP or hepatology specialist about cannabis use, including frequency and method
• Request baseline and periodic liver function tests (LFTs)
• Avoid smoking; prefer vaporisation or sublingual products
• Minimise alcohol consumption
• Use the lowest effective dose
• Avoid products with unverified potency or undisclosed ingredients
• Monitor for symptoms including fatigue, abdominal pain, or jaundice

Medical Cannabis on the NHS

Obtaining medical cannabis through the NHS remains challenging, with specialist neurologists and paediatricians prescribing primarily for epilepsy and certain multiple sclerosis patients. For those accessing cannabis outside NHS pathways, independent health screening becomes more crucial, particularly regarding liver function.

Conclusion

Cannabis does not appear to directly damage the liver in the manner of alcohol or some other toxins. However, the relationship between cannabis and liver disease in the UK context remains nuanced and deserves individual medical assessment. Those with existing liver conditions, hepatitis, or cirrhosis should exercise particular caution and maintain close liaison with healthcare providers.

The evidence supporting cannabis safety in liver disease patients remains limited. Future research, coupled with better regulation of cannabis products in the UK, will likely clarify these interactions further. Until then, informed decision-making with medical guidance remains essential for anyone using cannabis whilst managing liver health concerns.

“`

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Always consult a qualified healthcare professional. CannaZen is an information platform, not a medical provider.